Chronic cerebral arterial occlusion and moyamoya disease are significant causes of stroke, particularly in regions where ...

Tenaya is currently implementing amendments to the study protocol in collaboration with MyPEAK-1 clinical sites after which the company plans to resume dosing. The protocol changes standardize ...

Discover why IQVIA Holdings leads in life sciences data & tech with AI-driven services, strong growth, and up to 30% stock ...

Introduction Prescribing high-dose antipsychotics is typically reserved for individuals with treatment-resistant severe ...

Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents This study reviewed all industry-sponsored phase I clinical trial protocols ...

Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in ...

The Fast Company Impact Council is an invitation-only membership community of leaders, experts, executives, and entrepreneurs who share their insights with our audience. Members pay annual dues for ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Nexalin Technology launched a virtual clinic to enhance patient treatment and data management for its HALO™ headset in clinical studies. Nexalin Technology, Inc. has announced the successful launch of ...